Früher, länger, besser – Krankheitskontrolle der atopischen Dermatitis

In der Therapie von Menschen mit atopischer Dermatitis (AD) kommt es auf eine rasche und lang anhaltende Linderung sowohl der Ekzeme als auch des Juckreizes an. Erfolgversprechend ist hier eine frühe Behandlung. Bei mittelschwerer und schwerer AD kommen auch Systemtherapien zum Einsatz. Biologika oder Januskinase (JAK)-Inhibitoren gelten als die neuen Standardtherapien. Diese modernen Wirkstoffe haben in etlichen randomisiert-kontrollierten Zulassungsstudien überzeugt.

• Literatur

• 1 S3-Leitlinie „Atopische Dermatitis“ (AWMF-Registernr. 013–027). 2023 Accessed March 07, 2025 at: https://register.awmf.org/de/leitlinien/detail/013-027
• 2 Chopra R, Vakharia PP, Sacotte R. et al. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol 2017; 177: 1316-1321
• 3 Yosipovitch G, Reaney M, Mastey V. et al. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol 2019; 181: 761-769
• 4 Fachinformation Dupixent, aktueller Stand.
• 5 Fachinformation Adtralza, aktueller Stand.
• 6 Fachinformation Ebglyss, aktueller Stand.
• 7 EMA: Nemolizumab. Accessed July 30, 2025 at: https://www.ema.europa.eu/en/medicines/human/EPAR/nemluvio
• 8 Silverberg JI, Yosipovitch G, Simpson EL. et al. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS. J Am Acad Dermatol 2020; 82: 1328-1336
• 9 Blauvelt A, de Bruin-Weller M, Gooderham M. et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017; 389: 2287-2303
• 10 Simpson EL, Wollenberg A, Soong W. et al. Patient-oriented measures for phase 3 studies of tralokinumab for the treatment of atopic dermatitis (ECZTRA 1, 2, and 3). Ann Allergy Asthma Immunol 2022; 129: 592-604.e5
• 11 Willen C. Neue Option bei atopischer Dermatitis in Aussicht. hautnah dermatologie 2020; 36: 76
• 12 Wollenberg A, Blauvelt A, Guttman-Yassky E. et al. Tralokinumab for moderate-tosevere atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol 2021; 184: 437-449
• 13 Rand K, Ramos-Goñi JM, Akmaz B. et al. Matching-adjusted indirect comparison of the long-term efficacy maintenance and adverse event rates of lebrikizumab versus dupilumab in moderate-to-severe atopic dermatitis. Dermatol Ther (Heidelb) 2024; 14: 169-182
• 14 Accessed March 07, 2025 at: https://www.bfarm.de/shareddocs/risikoinformationen/pharmakovigilanz/de/rhb/2023/rhb-januskinase.html
• 15 Fachinformation Rinvoq, aktueller Stand.
• 16 Fachinformation Cibinqo, aktueller Stand.
• 17 Fachinformation Olumiant, aktueller Stand.
• 18 Guttman-Yassky E, Thaci D, Pangan AL. et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol 2020; 145: 877-884
• 19 Blauvelt A, Teixeira HD, Simpson EL. et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 2021; 157: 1047-1055
• 20 Reich K, Silverberg JI, Papp KA. et al. Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study. J Eur Acad Dermatol Venereol 2023; 37: 2056-2066
• 21 Simpson EL, Silverberg JI, Nosbaum A. et al. Integrated safety update of abrocitinib in 3802 patients with moderate-to-severe atopic dermatitis: data from more than 5200 patient-years with up to 4 years of exposure. Am J Clin Dermatol 2024; 25: 639-654
• 22 Simpson EL, Lacour JP, Spelman L. et al. Baricitinib in patients with moderate-tosevere atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol 2020; 183: 242-255
• 23 Waldman RA, Sharp KL, Adalsteinsson JA. et al. Herpes zoster subunit vaccine for patients initiating a janus kinase inhibitor. J Am Acad Dermatol 2023; 88: 697-698